Number 39

Therapeutic cancer vaccines there’s a new kid on the block

Cutting Edge 10 November 2010 0

Efforts to treat cancers using vaccines have seen many false dawns. Now the first therapeutic cancer vaccine has won approval for treating prostate cancer, with more waiting in the wings. Could compounds that teach the [more]

... [ more ]

Fake drugs pose a threat to Europe’s cancer patients

Editorial 1 November 2010 0

The counterfeit drugs trade, once largely confined to the developing world, is now firmly established in western countries. Greater vigilance from the cancer community is need. Download full article

... [ more ]

Sara Faithfull: unleashing the potential of cancer nursing

Cover Story 1 November 2010 0

Many cancer nurses are still undervalued and underused, with few opportunities for specialist training and little guidance on best practice. Sara Faithfull is working to change all that. Download full article

... [ more ]

Cancer of unknown primary: a diagnostic and therapeutic dilemma

Grandround 1 November 2010 0

Cancer of unknown primary origin is difficult to manage because, even when the primary can be detected, it behaves differently to cancers of the same type and location that are discovered as primaries. Download full [more]

... [ more ]

Shining a light on nanoparticle therapy

Spotlight on 1 November 2010 0

Steering the right course between simplistic talk of wonder drugs’ and baffling readers with unnecessary scientific detail can be tricky. Mark Henderson, of the UK national daily The Times, won a Best Cancer Reporter Award [more]

... [ more ]

Steadfast in Sarajevo

Spotlight on 1 November 2010 0

Half the staff at the Clinical Centre left and 50 were killed during the siege of Sarajevo. But Hiba Basic stuck to her post and took over the oncology department. Download full article

... [ more ]

The Clinical Trials Directive: can we get it right second time around?

Spotlight on 1 November 2010 0

Though well-intended, the European Clinical Trials Directive severely impeded clinical research. The Commission is now trying to revise the Directive, and is inviting researchers, patient groups and others to submit concrete suggestions. Download full article

... [ more ]

200 mg-m2 melphalan the gold standard for multiple myeloma

Impact Factor 1 November 2010 0

Palumbo and co-authors report on the results of a randomised trial comparing two doses of melphalan in patients with symptomatic multiple myeloma. Overall complete response rates, median progression-free survival and projected five-year overall survival were [more]

... [ more ]